Trial Profile
A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Onfekafusp alfa (Primary) ; Doxorubicin
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms FIBROSARC
- Sponsors Philogen
- 05 Apr 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 05 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 20 Feb 2024 According to a Philogen media release, , the study has enrolled 97 out of 118 patients across 24 clinical centers in Germany, Italy, France, Poland, and Spain. The enrolment of 118 patients is expected to be completed in 2024.